65,437 trials
Arthroplasty, Replacement, Knee · Thromboembolism
Primary: Number of Participants With Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period — 183; 213; 193 Participants — p=0.6648
Arthroplasty, Replacement, Knee · Venous Thrombosis
Primary: Percentage of Participants Who Have a Composite Endpoint Consisting of Total Venous Thromboembolic Event (VTE) and All Cause Mortality During the Treatment Period…
Venous Thromboembolism
Primary: Number of Participants With Venous Thromboembolic (VTE) Events — 86; 49; 39; 47 participants — p=<0.0001
Severe Sepsis
Primary: Mean Change in Protein C Levels From Day 1 to Day 7 — 55; 52; 79; 83 Percent Protein C Activity — p=0.011
Herpes Zoster
Primary: Varicella-zoster Virus (VZV) Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Antibody Responses — 553.5; 588.7 gpELISA units/mL
Restless Legs Syndrome
Primary: Summary of Change From Baseline in Total Sum of McGill Pain Questionnaire to Visit 3 — -14.48 Scores on scale
Schizophrenia
Primary: Mean Change From Baseline in the Composite Score From the Brief Assessment of Cognition in Schizophrenia (BACS) Battery After 2 Weeks of Treatment — 0.3; 1.5 T-score…
Asthma · Coronary Artery Disease · Pulmonary Disease, Chronic Obstructive
Primary: Percentage of Subjects Who Had a >15% Decrease in Forced Expiratory Volume in 1 Second (FEV1) at the 2-hour Postbaseline Assessment — 2.9; 1.1; 5.4; 4.2 Percentage of…
Herpes Zoster
Primary: Vaccine-related Serious Adverse Experiences (SAEs) for 28 Days Postvaccination — 0; 0; 100; 101 Participants
Hypertension
Primary: Pulse Wave Velocity (PWV) Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug — 0.28; -0.12 meters/second
Hypertension
Primary: Change From Baseline to Week 4 in Office Cuff Mean Sitting Systolic Blood Pressure (MSSBP) — 166.2; 164.5; 164.5; 157.5 mm Hg
Hepatitis B, Chronic (CHB)
Primary: Number of Participants With a Combined Response Consisting of All Three Responses - (a) Serological Response, (b) Virological Response, and (c) Biochemical Response — 0…
Fabry Disease
Primary: Number of Participants Experiencing a Clinically Significant Renal, Cardiac or Cerebrovascular Event and/or Death in Fabrazyme (Agalsidase Beta) Patients as Compared to…
Carcinoma, Renal Cell
Primary: Progression-free Survival (PFS) Based on Independent Radiological Review for the First Intervention Period — 5.7; 5.6 months — p=0.50
Skin Aging
Primary: Skin Aging Measured With the Photonumeric Scale. — 21.25; 21.36; 21.21; 21.03 Units on a scale